openPR Logo
Press release

Tyrosine Kinase Inhibitors Market is Projected to Surpass US$ 19.0 Bn by 2026

11-09-2020 10:10 AM CET | Health & Medicine

Press release from: Transparency Market Research

Tyrosine Kinase Inhibitors Market is Projected to Surpass US$

The global tyrosine kinase inhibitors market was valued at US$ 18.3 Bn in 2017. It is projected to expand at a compound annual growth rate (CAGR) of 0.02% from 2018 to 2026, according to a new report published by Transparency Market Research (TMR) titled “Tyrosine Kinase Inhibitors Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. The report suggests that rising awareness about cancer diagnosis and treatment and expanding indications of existing & pipeline TKIs are expected to boost the tyrosine kinase inhibitors market in the near future.

Read Report Overview - https://www.transparencymarketresearch.com/tyrosine-kinase-inhibitors-market.html

North America and Europe are projected to dominate the global market owing to high prevalence and increase in incidence of cancer and the high rate of norms for drug import initiatives to attract healthcare providers and pharmaceutical companies in order to establish their base and drug pricing regulations, which are likely to drive growth of oncology market. This, in turn, is augmenting the tyrosine kinase inhibitors market in North America and Europe.

The market in Asia Pacific is projected to witness expansion at a significant growth rate during the forecast period. Expansion of the market in Asia Pacific is attributed to high prevalence and increase in incidence rate of cancer and rise in health care expenditure in Asia Pacific. The market for tyrosine kinase inhibitors in Latin America is likely to expand at a moderate growth rate during the forecast period.

Request a PDF Sample - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=40667

Specificity and efficacy of TKIs over chemotherapy and radiotherapy to fuel global market

The global tyrosine kinase inhibitors market is projected to be potentially driven by the high prevalence and increase in incidence of cancer across the globe. Moreover, tyrosine kinase inhibitors were accepted largely due to specificity and efficacy and benefits over chemotherapy and radiotherapy. For instance, BCR-ABL TKIs, which were earlier approved for treating CML, are not indicated for treating acute lymphoblastic leukemia (ALL) and gastrointestinal tumors. Similarly, EGFR TKIs are approved for an array of indications such as pancreatic cancer, breast cancer, and non-small cell lung cancer. Tyrosine kinase inhibitors manufacturing companies provide diverse features and benefits to cancer patients, from chemotherapy and radiotherapy treatment procedures, which can be utilized by physicians to treat cancer patients.

Key players and researchers have invested to develop new and advanced tyrosine kinase inhibitors with less toxicity and adverse effects. Researchers are applying various approaches to tackle this issue such as modification of molecular structure and use of excipient. This is likely to introduce a new class of TKIs that offer better efficacy and safety. Companies are focusing on the development of tyrosine kinase inhibitors therapy by multi-targeting feature. Multi-kinase targeting TKIs offer better drug stability and patient acceptance such as Sorafenib (Nexavar), Cabozantinib (Cometriq), Axitinib (Inlyta) and under development TKIs such as TSU-68, Brivanib, and Cediranib (Recentin) are likely to augment the product life cycle and widen the application areas during the next few years.

VEGFR tyrosine kinase inhibitors is projected to be highly lucrative product segment

VEGFR tyrosine kinase inhibitors are projected to be more efficient in treating various soft cell sarcomas. Their multi-targeted kinase inhibitor activity is likely to augment their usage during the forecast period. Patent expiry of blockbuster BCR-ABL TKIs, availability of generics, and introduction of more efficient alternatives are likely to hamper the BCR-ABL TKIs segment during the forecast period. Hence, the use of VEGFR tyrosine kinase inhibitors for cancer treatment is likely to increase during the forecast period. However, vast applications of VEGFR TKIs in treating various types of cancers and their high efficacy are likely to augment the segment during the forecast period. Furthermore, several VEGFR TKIs are multi-targeted, which further expands their application areas and is likely to contribute to their off-label use for treating various types of cancers.

Request for Analysis of COVID-19 Impact on Tyrosine Kinase Inhibitors Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=40667

Incidence of Lungs Cancer is likely to propel the tyrosine kinase inhibitors market

Lung cancer is the leading cause of death in the world. An estimated 1.8 million new cases of lung cancer are reported each year across the world. TKIs are preferred to treat non-small cell lung cancer, which accounts for 85% of the total lung cancer cases. Increase in incidence of lung cancer and introduction of new tyrosine kinase inhibitors for the treatment of non-small-cell lung carcinoma is likely to propel the segment during the forecast period.

Independent pharmacies segment dominates the market and online pharmacies segment is estimated to expand at a prominent CAGR during the forecast period

In terms of distribution channel, the independent pharmacies segment accounted for a leading share of the global tyrosine kinase inhibitors market. It is estimated to gain market share by the end of 2026, expanding at a CAGR more than 0.20% during the forecast period. Wide network of independent pharmacies and expansion of international pharmacy service providers across the global are likely to propel the independent pharmacies segment in the global tyrosine kinase inhibitors market. Online pharmacies offer convenience and discounts, which is likely to attract new customers. Moreover, increase in adoption of e-commerce is likely to augment the segment. However, concerns about counterfeit medicines, medication, and delivery errors are likely to hamper the segment between 2018 and 2026.

Asia Pacific offers potential business development opportunity

North America and Europe accounted for a key share of the global tyrosine kinase inhibitors market in 2017. These are likely to saturate in market share by the end of 2026. High prevalence of cancer, increase in health care expenditure in countries in Eastern and Central Asia Pacific countries, and government initiatives to promote the usage of tyrosine kinase inhibitors in therapy have contributed to the leading share held by these regions in the global tyrosine kinase inhibitors market. Asia Pacific is projected to be a highly attractive market for tyrosine kinase inhibitors, and is likely to exhibit a considerably high attractiveness index during the forecast period. The market in Asia Pacific is projected to expand at a high CAGR of more than 0.14% during the forecast period due to the rise in incidences of lungs cancer in emerging countries such as India and China. Furthermore, well-established healthcare facilities, and high adoption of digital healthcare technology in countries such as Japan, Australia & New Zealand, Malaysia, and Singapore are likely to fuel the market in Asia Pacific. The market in Latin America is anticipated to expand at a moderate growth rate during the forecast period.

Buy tyrosine kinase inhibitors market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=40667<ype=S

Key trend of R&D to increase FDA breakthrough therapy observed among leading players

The report also provide profiles of leading players operating in the global tyrosine kinase inhibitors market. Novartis AG, Bristol-Myers Squibb Company, Pfizer Inc., and Johnson & Johnson are some of the leading players operating in the global tyrosine kinase inhibitors market and account for a significant market share. Companies operating in the tyrosine kinase inhibitors industry are focusing on increasing their geographic presence by means of strategic acquisitions and collaborations with leading players & increasing FDA approvals of therapeutic drugs in their respective domains and geographies. In February 2018, U.S., EU and Japan Health authorities accept regulatory submissions for review of Pfizer's third-generation ALK Inhibitor Lorlatinib. Other prominent players operating in the global tyrosine kinase inhibitors include AstraZeneca Plc, Bayer AG, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., Eisai Co., Ltd., and Eurofarma Laboratórios S/A.

More Trending Reports by Transparency Market Research –

Teleradiology Market: https://www.biospace.com/article/teleradiology-market-computed-tomography-ct-segment-held-major-share-in-the-market/

Read our Case study at https://www.transparencymarketresearch.com/casestudies/innovative-medical-device-manufacturing-start-up

Contact

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Tyrosine Kinase Inhibitors Market is Projected to Surpass US$ 19.0 Bn by 2026 here

News-ID: 2183449 • Views:

More Releases from Transparency Market Research

Handheld Marijuana Vaporizer Market Key Drivers, Market Research, and Insights for the USD 15.9 Bn Market 2022-2031
Handheld Marijuana Vaporizer Market Key Drivers, Market Research, and Insights f …
The global handheld marijuana vaporizer market has witnessed remarkable growth in recent years, attributed to the increasing acceptance of medicinal marijuana and the demand for convenient and discreet consumption methods. Valued at US$ 5 billion in 2021, the market is projected to surge at a CAGR of 13.4% to reach US$ 15.9 billion by 2031. This article delves into the factors driving this growth, the evolving market landscape, and the
Disinfectant Wipes Market Forecast 2020-2030 - Market Size, Drivers, Trends, And Competitors
Disinfectant Wipes Market Forecast 2020-2030 - Market Size, Drivers, Trends, And …
The COVID-19 pandemic has precipitated a remarkable surge in the demand for disinfectant products, with a notable emphasis on disinfectant wipes as an essential tool in maintaining hygiene and preventing the spread of pathogens. This research report delves into the multifaceted landscape of the disinfectant wipes market, elucidating key trends, drivers, and innovations shaping the industry. 𝐆𝐞𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐭𝐡𝐢𝐬 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐫𝐞𝐩𝐨𝐫𝐭 @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=70359 Key Players and Market Developments Key players
Tissue Banking Market is Expected to Reach US$ 2,903.3 Million to 2026| TMR Study
Tissue Banking Market is Expected to Reach US$ 2,903.3 Million to 2026| TMR Stud …
The global 𝐭𝐢𝐬𝐬𝐮𝐞 𝐛𝐚𝐧𝐤𝐢𝐧𝐠 𝐦𝐚𝐫𝐤𝐞𝐭 reached a value of US$ 1,056.4 million in 2017 and is projected to nearly triple to US$ 2,903.3 million by 2026, with a robust Compound Annual Growth Rate (CAGR) of approximately 12.0% from 2018 to 2026. Factors such as increasing awareness about tissue donation, technological advancements, and a growing target patient population are anticipated to propel market growth during this period. Moreover, the market is expected
Vascular Closure Devices Market to reach US$ 1 Billion by 2027: TMR Study
Vascular Closure Devices Market to reach US$ 1 Billion by 2027: TMR Study
This report by Transparency Market Research, Inc. assesses the present state and future growth potential of the global 𝐯𝐚𝐬𝐜𝐮𝐥𝐚𝐫 𝐜𝐥𝐨𝐬𝐮𝐫𝐞 𝐝𝐞𝐯𝐢𝐜𝐞𝐬 𝐦𝐚𝐫𝐤𝐞𝐭. It features a comprehensive executive summary, offering insights into various segments of the market. Additionally, the report provides detailed analysis and data on product, access type, application, end user, and regional segments within the global market. Vascular closure devices is estimated to reach a value of ~US$ 1 Bn

All 5 Releases


More Releases for TKIs

Tyrosine Kinase Inhibitors Market Size Statistics, Facts and Figures
The global tyrosine kinase inhibitors market was valued at US$ 18.3 Bn in 2017. It is projected to expand at a compound annual growth rate (CAGR) of 0.02% from 2018 to 2026, according to a new report published by Transparency Market Research (TMR) titled "Tyrosine Kinase Inhibitors Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018-2026". The report suggests that rising awareness about cancer diagnosis and treatment and
01-22-2020 | Health & Medicine
TMR
Tyrosine Kinase Inhibitors Market Overall Study Report Analysis 2018 - 2026
The global tyrosine kinase inhibitors market was valued at US$ 18.3 Bn in 2017. It is projected to expand at a compound annual growth rate (CAGR) of 0.02% from 2018 to 2026, according to a new report published by Transparency Market Research (TMR) titled “Tyrosine Kinase Inhibitors Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. The report suggests that rising awareness about cancer diagnosis and treatment and
01-22-2020 | Health & Medicine
TMR
Pediatric Neuroblastoma Treatment Market 2018-2026 | Evolving Opportunities with …
The global tyrosine kinase inhibitors market was valued at US$ 18.3 Bn in 2017. It is projected to expand at a compound annual growth rate (CAGR) of 0.02% from 2018 to 2026, according to a new report published by Transparency Market Research (TMR) titled “Tyrosine Kinase Inhibitors Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. The report suggests that rising awareness about cancer diagnosis and treatment and
Chronic Myelogenous Leukemia Treatment Market is Registering 6.7% CAGR During 20 …
Majorly, chronic myelogenous leukemia (CML) occurs in adults, however, it sometimes occurs in children as well. However, targeted drugs called Tyrosine-Kinase Inhibitors (TKIs) have been effective in providing long-term survival rates. Meanwhile, the Food and Drug Administration (FDA) has recently approved dasatinib (Sprycel) for the treatment of chronic myelogenous leukemia in children. As the chronic myeloid leukemia is more aggressive in younger patients, the approval of drugs can help in
Chronic Myelogenous Leukemia Treatment Market Value to Reach US$ 8,550.8 Million …
Majorly, chronic myelogenous leukemia (CML) occurs in adults, however, it sometimes occurs in children as well. However, targeted drugs called Tyrosine-Kinase Inhibitors (TKIs) have been effective in providing long-term survival rates. Meanwhile, the Food and Drug Administration (FDA) has recently approved dasatinib (Sprycel) for the treatment of chronic myelogenous leukemia in children. As the chronic myeloid leukemia is more aggressive in younger patients, the approval of drugs can help in
Chronic Myelogenous Leukemia Treatment Market is estimated to bring in US$ 8,550 …
Global Chronic Myelogenous Leukemia Treatment Market to Witness Robust Growth during the forecast period 2017-2026 As per the latest report by Transparency Market Research (TMR), the global chronic myelogenous leukemia market is expected to witness strong growth. The market is estimated to register 6.7% CAGR during the forecast period 2017-2026. It is also expected to reach US$ 8,550.8 million revenue by the end of 2026. The global chronic myelogenous leukemia market is